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determination of salicylate in plasma. However, for econ-
omy many clinical laboratories still measure salicylate in
plasma by Trinder’s colorimetric procedure (4), even
though Trinder’s reagent contains mercuric salt, which is
hazardous for the environment. Here we report an alterna-
tive for Trinder’s reagent for rapid and economical deter-
mination of salicylate in plasma.
We mix by hand inversion 10 L of sample (plasma or
aqueous standard) with 10 mL of 0.1 molJL ammonium
hydroxide in glass-distilled water in a 16 x 100 mm glass
tube. We then measure the fluorescence of the diluted
sample at Aex = 306 nm and Aem = 400 nm, using a Model
650-15 fluorospectrophotometer (Perkin-Elmer, Norwalk,
CT 06859-0012).
The observed fluorescence of aqueous and plasma salic-
ylate standards is similar and is linearly related to salicy-
late concentrations from 0.1 to 8.0 mmolJL. The presence of
increased concentrations of protein (12 g/L), bilirubin (35
p.mollL), hemoglobin (0.5 gIL), and triglycerides (5 mmollL)
did not lead to any decrease in the observed fluorescence in
various plasma samples supplemented with 2 mmol of
salicylate per liter. Analysis of 25 plasma samples known
to be salicylate-free gave fluorescence values corresponding
to salicylate concentrations of 0.05 to 0.2 mmol/L. Acidic
drugs that, like salicylate, have relatively high therapeutic
concentrations (e.g., acetaminophen, ibuprofen, tolmetin,
sulindac, and diclofenac) gave insignificant values for sa-
licylate when plasma supplemented with these drugs at a
concentration of 1 g/L was analyzed by the described
procedure in separate experiments. However, diflunisal, an
analog of salicylate, gave a fluorescence response similar to
that of salicylate. Chlorproma.zine, one of the commonly
prescribed phenothiazines, does not show any fluorescence
response at a concentration of 1 g/L by this procedure.
Acetylsalicylate in plasma is, for all practical purposes,
present as salicylate and is measured as such.
To check reproducibility, we analyzed Therachem#{174} low
and high therapeutic drug controls (Fisher Scientific,
Orangeburg, NY 10962). The results show acceptable pre-
cision and accuracy, comparing well with the values ob-
mined by the Abbott TDx procedure:
Within batch 0.51 0.80 2.88
Between batch 0.49 6.48 2.83
n = 10 each.
 Mean values (and range) obtained by Abbott TDx as reported in Fisher’s
product insert.
Several fluorometric procedures for the determination of
plasma salicylate have been described and applied for
pharmacokinetic studies of salicylate because of the high
sensitivity and specificity provided by fluorescence proce-
dures. In most cases, samples have been prepared for
fluorescence measurement by extraction with organic sol-
vents and back-extraction into the aqueous phase (5); in
some cases, proteins have been removed by precipitation
with tungstic-sulfuric acid reagent (6). Recently, a direct
fluorometric procedure in the presence of EDTA and ter-
bium salts and without the removal of proteins has been
described (7). The procedure we describe is economical and
compatible with the environment.
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Screening for Pauclalbuminurla with Frozen Urine
Samples, Bernhard K. Kramer, Christiane M. Erley, Inge
Lindena, and Teut Risler (Section of Nephrol. and
Hypertension, HI. Dept. of Internal Med., Univ. of
Tubingen, Otfried-Muller-Str. 10, D-7400 Tubingen,
F.R.G.)
Paucialbuminuria (“microalbuminuria”), a strong pre-
dictor of future overt nephropathy in type I diabetic pa-
tients, can be stopped or even reversed by control of blood
pressure and (or) blood glucose, thus probably slowing or
preventing development of overt diabetic nephropathy (1).
A decrease in albumin concentration in samples stored at
-20 #{176}C(2, 3) and uncertain effects of centrifugation before
assay (4,5) have recently been reported. Therefore our aim
in this study was to examine what effects storage at
-20 #{176}C,centrifugation before assay, or urinary pH might
have on urinary albumin concentration.
We studied 43 urine specimens after storage at -20 #{176}C
for two weeks and three months. Albumin concentration
was measured by enzyme-linked immunosorbent assay as
described previously (6). Albumin concentrations decreased
significantly (statistical evaluation by analysis of variance,
Student-Newman-Keuls test) after three months of stor-
1.17 age but not after two weeks (Table 1). Coating the storage
5.9 tubes with casein to prevent adsorption of albumin to the
tube as well as centrifugation before assaying the albumin
concentration had no consistent effect on the decrease of
albumin concentrations (Table 1). The pH was significantly
lower (P < 0.02) in samples in which the albumin concen-
tration decreased compared with that in samples with no
decrease (pH 5.75 ± 0.23 vs 6.46 ± 0.13, respectively).
The number of urine samples with visible precipitation
increased during storage (44% after three months); those
samples also tended to have lower pH values (P> 0.05), but
the presence of precipitates was not clearly correlated with
the decrease of albumin content during prolonged storage.
The possibility that storage conditions of urine samples
may affect albumin measurement must be taken into
account when monitoring or detecting paucialbuminuria.
Storing urine samples before determination of albumin
concentration is not recommended for periods markedly
exceeding two weeks.
Table 1. Urinary Albumin Excretion Determined from Samples Stored at -20 #{176}Cfor Two Weeks and for Three
Months
Mean (SD)
Alcohol
consumption Controls
1692 CLINICAL CHEMISTRY, Vol. 36, No. 9, 1990
Treatment’
Uncoated + uncentnfuged
Uncoated + centrifuged
Coated + uncentrifuged
Coated + centrifuged
Day 1
39.69 ± 5.32
38.62 ± 4.99
41.37 ± 5.20
44.95 ± 5.84
Albumin excretIon, moan ± SEM, mg/24 h
Week 2
40.05 ± 5.63
44.73 ± 6.87
40.40 ± 5.32
45.42 ± 5.84
Month 3
37.89 ± 5.67
35.25 ± 5.26
31.88 ± 4.38
36.96 ± 5.27
Samples stored in either coated or uncoated tubes with or without centrifugation before assay.
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Effects of Four Days of Regular, Moderate
Consumption of Ethanol on High-Density Lipoprotein
Cholesterol Concentrations in Plasma, L. 0. Howes,
H. Krum, and P. A. Phillips (Clin. Pharmacol. and
Therapeutics, Austin Hospital, Heidelberg, Victoria,
3084, Australia)
Increases in concentrations of triglycerides and urate in
plasma are generally perceived as early biochemical mark-
ers of substantial increases in alcohol (ethanol) consump-
tion. In recent years it has become apparent that alcohol
consumption is also associated with an increase in high-
density lipoprotein (HDL) cholesterol in plasma. However,
the time course of the changes in concentrations of HDL
cholesterol in plasma in relation to changes in alcohol
consumption has not been adequately determined. In a
previous study comparing the effects of six weeks of con-
sumption of low-alcohol beer with that of ordinary beer,
Masarei et al. (1) found that changes in the apoprotein A
content of HDL was a more sensitive indicator of change in
alcohol consumption than were either triglyceride, uric
acid, or gamma-glutamyltransferase (gamma-GT; EC
2.3.2.2) activity. In the present study we have compared the
effects of regular alcohol consumption over a four-day
period with a similar period of abstaining from alcohol on
the concentrations in plasma of lipoproteins, uric acid, and
gamma-GT.
Twelve healthy male volunteers, ages 18-65, either
consumed alcohol, 1 g/kg of body weight per night, for four
nights or abstained from alcohol and consumed an isoca-
loric glucose substitute for four nights in a randomized
cross-over study. At least four days separated each study
phase. On the final morning of each study phase, venous
blood was collected with an indwelling cannula from the
subjects after 15 mm of supine rest. There were no signif-
icant changes in calorie intake or body weight between the
two study phases. The HDL cholesterol increased signifi-
cantly after this relatively brief period of regular alcohol
consumption and accounted for an increase in total choles-
terol that almost achieved statistical significance (P =
0.066). In contrast, concentrations of low-density lipopro-
tein (LDL) cholesterol, triglyceride, uric acid, and gamma-
GT remained unaltered. The plasma hematocrit also re-
mained unaltered.
Cholesterol, mmol/L
Total 5.47 (0.91) 5.23 (0.86)
HDL 1.35 (0.20)a 1.23 (0.19)
LDL 3.32 (0.76) 3.26 (0.72)
Triglyceride, mmol/L 1.79 (0.79) 1.66 (0.75)
Uric acid, mol/L 0.36 (0.07) 0.36 (0.05)
Gamma-GT, U/L 20.8 (11.1) 20.2 (10.7)
a Significantly different from control values: P = 0.001 (Student’s paired
f-test).
These data demonstrate that (a) the changes in plasma
HDL cholesterol that are associated with increased alcohol
consumption occur rapidly and (b) changes in HDL choles-
terol in plasma are a more sensitive marker of short-term
alterations in alcohol consumption than are triglyceride,
uric acid, or gainma-GT.
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Interpretation of a 2-h Change in the Serum
Concentration of Creatine Kinase 2, J. Valero-Politi, A.
Rivera-Coil, and X. Fuentes-Arderiu (Servei de Bioquim.
Cliii., Hosp. Princeps d’Espanya, 08907 L’Hospitalet de
Liobregat, Barcelona, Spain)
Measurement of the catalytic concentration of creatine
kinase 2 (also known as CK-MB) in serum is one of the
main tests for the diagnosis of acute myocardial infarction.
When the isoenzyme measurement does not clearly reflect
